RheumNow

Colchicine Ineffective in Long COVID Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers. https://buff.ly/KCrJ9Xf

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and prevent autoimmune disease. https://buff.ly/dE2Poex

💬A JAKi CHAT: Shared Decision-Making in RA Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations, including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact.

Single center study ANCA-assoc. vasculitis. From 78 pts had poor outcomes (16 ESKD, 15 deaths). Elevated BUN was a risk factor (adj HR 1.07). Risk factors for ESKD were baseline BUN & WBC. Risks for death included CV Dz (HR 8.7), NLR (1.04) &anti-PLt Rx (HR 6.8)

5–10% of axSpA [ts jave comorbid IBD. Southern Swedish study 152 (r- & nr-) axSpA pts found elevated fecal calprotectin (≥ 50 mg/kg) & this was assoc. w/ more damage w/ higher mSASSS values for all axSpA (adj OR 2.2) & in r-axSpA (adj OR 2.9)

6-week intensive smoking cessation prg studied in 94 RA daily smokers in remission or low Dz activity (DAS28-CRP=2.9). At 3 mos the intervention group had higher cessation rates; but had no effect on EULAR responses, TJC, or CRP (result actually favoured the controls)

NEW EULAR POSTER: Real-world treatment patterns across the first 12 months of first-line advanced therapy in patients with PsA Compare treatment switching across first-line MOAs and treatments. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/yAztQdG

From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials

FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://buff.ly/my15Pnn

DERM on RheumNow (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow. https://buff.ly/3qkIJcJ